-
Product Insights
Pulmonary Embolism – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Embolism - Drugs In Development, 2023’, provides an overview of the Pulmonary Embolism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Deep Vein Thrombosis (DVT) – Drugs In Development, 2023
Global Markets Direct’s, ‘Deep Vein Thrombosis (DVT) - Drugs In Development, 2023’, provides an overview of the Deep Vein Thrombosis (DVT) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Venous (Vein) Thrombosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Venous (Vein) Thrombosis - Drugs In Development, 2023’, provides an overview of the Venous (Vein) Thrombosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Venous (Vein) Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Thromboembolism – Drugs In Development, 2023
Global Markets Direct’s, ‘Thromboembolism - Drugs In Development, 2023’, provides an overview of the Thromboembolism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Venous Thromboembolism – Drugs In Development, 2023
Global Markets Direct’s, ‘Venous Thromboembolism - Drugs In Development, 2023’, provides an overview of the Venous Thromboembolism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Venous Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thrombosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Thrombosis - Drugs In Development, 2023’, provides an overview of the Thrombosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vixarelimab in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vixarelimab in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vixarelimab in Idiopathic Pulmonary Fibrosis Drug Details: Vixarelimab (KPL-716) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rivaroxaban in Stroke
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rivaroxaban in Stroke Drug Details: Rivaroxaban is under development for the treatment of stroke and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rivaroxaban in Deep Vein Thrombosis (DVT)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rivaroxaban in Deep Vein Thrombosis (DVT) Drug Details: Rivaroxaban is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VCN-01 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VCN-01 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VCN-01 in Recurrent Head And Neck...